58757-38-3

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloronicotinoyl chloride is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its reactive nature allows for the formation of new chemical entities with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 6-chloronicotinoyl chloride serves as a precursor for the development of new agrochemicals, contributing to the creation of more effective and targeted pest control solutions.
Used in Dye Industry:
6-Chloronicotinoyl chloride is utilized in the production of various dyes, where its unique chemical properties enable the creation of a wide range of colorants for different applications.
Used in Chemical Synthesis:
As a highly reactive compound, 6-chloronicotinoyl chloride is employed in various chemical synthesis processes to produce a diverse array of chemical products, including specialty chemicals and intermediates for further reactions.

InChI:InChI=1/C6H3Cl2NO/c7-5-2-1-4(3-9-5)6(8)10/h1-3H

Upstream product

• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 2398-81-4 Nicotinic acid N-oxide 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 100790-99-6 Potassium; 6-chloro-nicotinate 
• 6311-35-9 6-bromonicotinic acid 
• 3510-66-5 2-Bromo-5-methylpyridine 
• 66572-55-2 6-methoxynicotinic acid 
• 53939-30-3 5-bromo-2-chloropyridine 
• 141-75-3 butyryl chloride 
• 5006-66-6 6-hydroxynicotinic acid 
• 18368-64-4 2-chloro-5-methylpyridine 

Downstream Products

• 54864-96-9 6-chloro-N,N-diethyl-nicotinamide 
• 224817-03-2 6-chloro-N-phenyl-nicotinamide 
• 49608-01-7 6-chloro-3-pyridinecarboxylic acid ethyl ester 
• 126918-39-6 6-Chloro-N-[(1S,2S)-2-(2,4-difluoro-phenyl)-2-hydroxy-1-methyl-3-[1,2,4]triazol-1-yl-propyl]-nicotinamide 
• 152328-60-4 1-(2-chloro-5-pyridyl)-2-phenylsulfonylethanone 
• 133476-33-2 6-Chloro-N-[3-(4-chloro-phenyl)-[1,3]thiazetidin-(2Z)-ylidene]-nicotinamide 
• 131886-22-1 6-chloro-N-(5-imidazol-1-yl-2-nitrophenyl)nicotinamide 
• 79567-66-1 2-chloro-5-benzoylpyridine 
• 123412-46-4 N-<(2-chloropyridin-5-yl)carbonyl>pyrrolidine-2-carboxylic acid 
• 68700-91-4 2-chloro-5-(1-hydroxy-1-methylethyl)pyridine 
• 21543-49-7 2-Chloro-5-hydroxymethylpyridine 
• 149281-42-5 6-chloro-N-methoxy-N-methylpyridine-3-carboxamide 
• 193964-29-3 (2-(4-methoxyphenyl)benzo[b]thiophene-3-yl)-(6-chloropyrid-3-yl)ketone 
• 55676-22-7 3-acetyl-6-chloropyridine 

Relevant academic research and scientific papers

Synthesis and crystal structure of N′-(6-chloropyridin-3-formyl)-N-t- butyl urea

The crystal structure of N′-(6-chloropyridin-3-formyl)-N-t-butyl urea, C11H14ClN3O2, has been established, and which belongs to monoclinic crystal system, space group Pn with unit cell dimensions a = 9.335(3) A, b = 12.715(3) A, c = 21.813(6) A, β = 95.417(6)°, V = 2577.6(12) A3 and Z = 8. An intramolecular N-H???O hydrogen bond forms a six-membered ring in the central part of the molecule. Both two N-H atoms of single unit participate in intermolecular hydrogen bonds and an intramolecular hydrogen bond, respectively. The crystal structure ofN′-(6-chloropyridin-3-formyl)- N-t-butyl urea, C11H14ClN3O2, has been established, and which belongs to monoclinic crystal system withZ = 8, space group Pn. [Figure not available: see fulltext.]

Pyrido[2,1-b]quinazolinecarboxylic acids as orally active antiallergy agents

A series of 8-substituted pyrido[2,1-b]quinazoline-2-carboxylic acids was prepared by the nickel carbonyl mediated carboxylation of the corresponding bromides. The activities of these compounds in the rat PCA test are comparable to those of the corresponding 2-substituted pyrido[2,1-b]quinazoline-8-carboxylic acids.

Synthesis of 6-chloronicotinates of steroidal 3β,5α,6β- triols and 3β,5-dihydroxy-6-ketones

New esters of 3β,5α,6β-trihydroxysteroids and 3β,5-dihydroxy-6-ketosteroids containing 6-chloropyridine groups characteristic of the alkaloid epibatidine were synthesized by acylation with 6-chloronicotinoylchloride.

Design, synthesis and agricultural evaluation of derivatives of N-Acyl-N-(m-fluoro-benzyl)-6-amino-coumarin

ABTRACT: This study aims to design and synthesize a series of N-Acyl-N-(m-fluoro- benzyl)-6- amino-coumarins through the principle of active substructure stitching, which are based on the core structure of N-(m-fluoro-benzyl)-6-amino-coumarin. The structures of target compounds e1–e25 have been characterized by 1H NMR, 13C NMR, ESI-MS and elemental analysis. Meanwhile, their agricultural activity have been evaluated in two weeds (Amaranth and Crabgrass) and four widespread noxious pathogens (V.mali, B.cinerea, F.axysporium and C.bacteria). The herbicidal activity results showed that almost all synthetic molecules have a greater impact on the stem system than on the root. Excellent inhibition rates were discovered from compounds e2–e5 and e20–e23 against Amaranth on stems, which were above 58percent(20 mg/L), 68percent(100 mg/L) respectively. Compounds e2 and e21 also exhibited striking inhibition on stems growth of both weeds. Anti-pathogenic activity showed that all the compounds exerted a better inhibitory activity on B.cinerea at 20 ppm compared to control carbendazim. All the heterocyclic substituted compounds (e17–e24, >57percent) made a better influence than the control (54.1percent) at the100 ppm. This research provides promising herbicidal and anti-pathogenic agents that have the better effects and can be potential for further development.

Synthesis of 2-methoxybenzamide derivatives and evaluation of their hedgehog signaling pathway inhibition

Aberrant hedgehog (Hh) signaling is implicated in the development of a variety of cancers. Smoothened (Smo) protein is a bottleneck in the Hh signal transduction. The regulation of the Hh signaling pathway to target the Smo receptor is a practical approach for development of anticancer agents. We report herein the design and synthesis of a series of 2-methoxybenzamide derivatives as Hh signaling pathway inhibitors. The pharmacological data demonstrated that compound 21 possessed potent Hh pathway inhibition with a nanomolar IC50 value, and it prevented Shh-induced Smo from entering the primary cilium. Furthermore, mutant Smo was effectively suppressed via compound 21. The in vitro antiproliferative activity of compound 21 against a drug-resistant cell line gave encouraging results. This journal is

Substituted formyldimethomorph (ethylpiperazine compound and) application thereof

The invention relates to substituted formyl morpholinoethyl piperazine compounds and an application thereof. The compounds are shown in a general formula (I) in the description, wherein R is phenyl, pyridyl, furyl, pyrazolyl, thiazolyl, thienyl or phenazi

Palladium-Catalyzed Chlorocarbonylation of Aryl (Pseudo)Halides Through In Situ Generation of Carbon Monoxide

An efficient palladium-catalyzed chlorocarbonylation of aryl (pseudo)halides that gives access to a wide range of carboxylic acid derivatives has been developed. The use of butyryl chloride as a combined CO and Cl source eludes the need for toxic, gaseous carbon monoxide, thus facilitating the synthesis of high-value products from readily available aryl (pseudo)halides. The combination of palladium(0), Xantphos, and an amine base is essential to promote this broadly applicable catalytic reaction. Overall, this reaction provides access to a great variety of carbonyl-containing products through in situ transformation of the generated aroyl chloride. Combined experimental and computational studies support a reaction mechanism involving in situ generation of CO.

NK1 receptor-targeting antagonist and application of same to chemotherapy-induced nausea and vomiting

The invention relates to a NK1 receptor-targeting antagonist and application of the same to chemotherapy-induced nausea and vomiting, belonging to the technical field of adjuvant therapeutics for tumor chemotherapy. The invention provides a compound as shown in a formula I which is described in the specification, or a racemate, stereoisomer, tautomer, isotopic label, oxynitride or pharmaceutically-acceptable salt thereof. The invention also provides a preparation method for the compound, a pharmaceutical compositions and the application of the compound or the racemate, stereoisomer, tautomer,isotopic label, oxynitride or pharmaceutically-acceptable salt thereof.

MONOCYCLIC COMPOUND

The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.

INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF

The invention provides novel chemical compounds useful for treating cancer, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.